Cartilage Therapy and Repair in Equine Athletes

Johnson, Sherry A.; Frisbie, David D.

doi:10.1053/j.oto.2016.06.005

Cited by 6 publications

(3 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 Clinically, IA MSCs are commonly used to treat equine athletes. 22 One clinical trial reported that a higher percentage of horses with femorotibial lesions returned to work with BMSC injection than with arthroscopic debridement alone. 16 Several human clinical trials have supported the use of IA MSCs for symptomatic improvement of OA and cartilage preservation.…”

mentioning

confidence: 99%

Integrin α10β1-Selected Mesenchymal Stem Cells Mitigate the Progression of Osteoarthritis in an Equine Talar Impact Model

et al. 2020

View full text Add to dashboard Cite

Background: Early intervention with mesenchymal stem cells (MSCs) after articular trauma has the potential to limit progression of focal lesions and prevent ongoing cartilage degeneration by modulating the joint environment and/or contributing to repair. Integrin α10β1 is the main collagen type II binding receptor on chondrocytes, and MSCs that are selected for high expression of the α10 subunit have improved chondrogenic potential. The ability of α10β1-selected (integrin α10high) MSCs to protect cartilage after injury has not been investigated. Purpose: To investigate integrin α10high MSCs to prevent posttraumatic osteoarthritis in an equine model of impact-induced talar injury. Study Design: Controlled laboratory study. Methods: Focal cartilage injuries were created on the tali of horses (2-5 years, n = 8) by using an impacting device equipped to measure impact stress. Joints were treated with 20 × 106 allogenic adipose-derived α10high MSCs or saline vehicle (control) 4 days after injury. Synovial fluid was collected serially and analyzed for protein content, cell counts, markers of inflammation (prostaglandin E2, tumor necrosis factor α) and collagen homeostasis (procollagen II C-propeptide, collagen type II cleavage product), and glycosaminoglycan content. Second-look arthroscopy was performed at 6 weeks, and horses were euthanized at 6 months. Joints were imaged with radiographs and quantitative 3-T magnetic resonance imaging. Postmortem examinations were performed, and India ink was applied to the talar articular surface to identify areas of cartilage fibrillation. Synovial membrane and osteochondral histology was performed, and immunohistochemistry was used to assess type I and II collagen and lubricin. A mixed effect model with Tukey post hoc and linear contrasts or paired t tests were used, as appropriate. Results: Integrin α10high MSC-treated joints had less subchondral bone sclerosis on radiographs ( P = .04) and histology ( P = .006) and less cartilage fibrillation ( P = .04) as compared with control joints. On gross pathology, less India ink adhered to impact sites in treated joints than in controls, which may be explained by the finding of more prominent lubricin immunostaining in treated joints. Prostaglandin E2 concentration in synovial fluid and mononuclear cell synovial infiltrate were increased in treated joints, suggesting possible immunomodulation by integrin α10high MSCs. Conclusion: Intra-articular administration of integrin α10high MSCs is safe, and evidence suggests that the cells mitigate the effects of joint trauma. Clinical Relevance: This preclinical study indicates that intra-articular therapy with integrin α10high MSCs after joint trauma may be protective against posttraumatic osteoarthritis.

show abstract

mentioning

confidence: 99%

Integrin α10β1-Selected Mesenchymal Stem Cells Mitigate the Progression of Osteoarthritis in an Equine Talar Impact Model

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Arthroscopy to remove debris and flush the joint with medicated fluids is considered palliative surgical care, whereas the use of marrow stimulation techniques, osteochondral grafting, autologous chondrocyte implantation, and augmentation with MSCs are some of the reparative or restorative techniques ( Johnson and Frisbie, 2016 ). It is important to note that any of these surgical procedures can be associated with other intra-articular therapies to achieve better results.…”

Section: Approach To Joint Treatmentmentioning

confidence: 99%

Osteoarthritis: a common disease that should be avoided in the athletic horse’s life

et al. 2022

View full text Add to dashboard Cite

“…[4] Regenerative therapies have become more common in the past few decades and are referred to as orthobiologics, [4,5] and include autologous-conditioned serum, [6,7] autologous-protein solution, [8-10] platelet-rich plasma, [11][12][13] and mesenchymal stem cells (MSCs). [14][15][16][17] Surgical interventions [4,[18][19][20] include bone-marrow stimulation, [21] autologous chondrocyte implantation (ACI), [22] and osteochondral grafting. [23] In many cases, the combination of surgical techniques and intraarticular therapies provide a better outcome.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Chondrogenic Potential of eBMSCs and eUCMSCs in Response to Selected Peptides and Compounds

Ajeeb,

Kiyotake,

Keefe

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Cartilage injuries pose significant challenges in horses and often lead to post-traumatic osteoarthritis (PTOA). Despite the advances in surgical and regenerative techniques, the result in most cases is the formation of a fibrocartilage repair tissue. Cell-based cartilage therapies are mainly focused on equine bone marrow-derived mesenchymal stem cells (eBMSCs) as they are easily accessible, and multipotent. Nonetheless, alternative allogeneic sources, for example equine umbilical cord matrix mesenchymal stromal cells (eUCMSCs), hold promise given their non-invasive and readily accessible nature. Considerable research has been dedicated to exploring chondroinductive factors (e.g., peptides and small compounds), aiming to replace growth factors for inducing chondrogenesis. However, these factors have not yet translated to the equine community. Therefore, in the current study, we selected from the literature two promising peptides, CM10 and CK2.1, and two promising compounds, kartogenin and SM04690, and assessed their chondroinductive potential with both eBMSCs and eUCMSCs. In addition, the chondroinductive potential of eBMSCs was evaluated in monolayer and spheroid culture in both hypoxia and normoxia in response to dexamethasone and/or TGF-β3. Results Following 21 days of culture, none of the evaluated chondrogenic factors resulted in a higher gene expression of chondrogenic markers compared to the positive or negative controls with eBMSCs or eUCMSCs. Interestingly, spheroid culture in hypoxia with dexamethasone treatment (without TGF-β or any compound or peptide) was sufficient to induce the chondrogenic differentiation of eBMSCs. Conclusion Based on cell response to the positive control, eBMSCs may be preferred over eUCMSCs for chondrogenesis. The current study therefore supports the use of spheroid culture, and the use of dexamethasone over TGF-β or any of the compounds or peptides tested here from the prior literature to drive chondrogenesis with eBMSCs.

show abstract

Cartilage Therapy and Repair in Equine Athletes

Cited by 6 publications

References 75 publications

Integrin α10β1-Selected Mesenchymal Stem Cells Mitigate the Progression of Osteoarthritis in an Equine Talar Impact Model

Integrin α10β1-Selected Mesenchymal Stem Cells Mitigate the Progression of Osteoarthritis in an Equine Talar Impact Model

Osteoarthritis: a common disease that should be avoided in the athletic horse’s life

Comparison of the Chondrogenic Potential of eBMSCs and eUCMSCs in Response to Selected Peptides and Compounds

Contact Info

Product

Resources

About